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PURPOSE. The p75NTR is a novel therapeutic target validated in a streptozotocin mouse model
of diabetic retinopathy. Intravitreal (IVT) injection of small molecule p75NTR antagonist THX-B
was therapeutic and resolved the inflammatory, vascular, and neurodegenerative phases of the
retinal pathology. To simplify clinical translation, we sought a superior drug delivery method
that circumvents risks associated with IVT injections.
METHODS. We compared the pharmacokinetics of a single 40 lg subconjunctival (SCJ) depot to
the reported effective 5 lg IVT injections of THX-B. We quantified therapeutic efficacy, with
endpoints of inflammation, edema, and neuronal death.
RESULTS. The subconjunctival depot affords retinal exposure equal to IVT injection, without
resulting in detectable drug in circulation. At week 2 of diabetic retinopathy, the SCJ depot
provided therapeutic efficacy similar to IVT injections, with reduced inflammation, reduced
edema, reduced neuronal death, and a long-lasting protection of the retinal structure.
CONCLUSIONS. Subconjunctival injections are a safe and effective route for retinal delivery of
p75NTR antagonists. The subconjunctival route offers an advantageous, less-invasive, more
compliant, and nonsystemic method to deliver p75NTR antagonists for the treatment of retinal
diseases.
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Ocular diseases affecting the posterior segment of theretina, such as diabetic retinopathy (DR), AMD, and
glaucoma are the major causes of blindness.1,2 Treatment of
these chronic pathologies has been challenging and very few
new drugs have been developed.
One challenge relates to the unique anatomic barriers and
physiology of the eye. To ensure that a drug reaches the retina,
specialists have used intravitreal (IVT) drug injections. Howev-
er, complications can occur in 1:300 injections (retinal tears or
detachment, vitreous hemorrhage and lens damage, infections,
elevated pressure, glaucoma, or cataracts3). In patients with DR
and AMD that often receive monthly IVT injections,4 these can
be serious and lead to poor compliance.
As an alternative, subconjunctival (SCJ) delivery may achieve
many drug delivery goals.5,6 However, few comprehensive
studies have been published on drug pharmacokinetics and eye
tissue distribution following SCJ injections (stability, retention
time, rate of elimination, drug concentration at the target
tissue).6–9 These parameters are likely to be drug specific or
target specific.
A second key challenge has been the lack of validated
druggable targets and lack of new mechanisms of action to
target.8,10–12 For diabetic retinopathy, current accepted thera-
pies include laser photocoagulation, intravitreal injections of
corticosteroids, anti-VEGF antibodies, and vitreoretinal sur-
gery.11–16 All these approaches are effective but are invasive,
costly, and are not novel mechanisms. No new drugs targeting
novel targets or disease mechanisms have been approved in
over 10 years.
The discovery and validation of novel therapeutic targets in
DR, with novel mechanisms of action combined with improved
drug delivery methods, would be an important contribution
solving these two problems.
The receptor p75NTR is a novel therapeutic target implicated
in many retinal degenerative diseases such as DR,17 experi-
mental glaucoma,18 and optic nerve damage.19 Specifically,
studies using a streptozotocin (STZ) mouse model of type I
diabetes demonstrated p75NTR-dependent induction of pro-
inflammatory agents TNFa and a2M, disruption of the neuroglia
vascular unit, blood–retina barrier (BRB) breakdown, edema,
and ganglion cell neuronal death. Moreover, in a model of
oxygen-induced retinopathy (OIR), the vaso-obliteration and
pathologic neovascularization also occur in a p75NTR-depen-
dent manner. Antagonizing p75NTR using IVT delivery of small
molecule THX-B diminished all these pathologic features in DR
and OIR.17
Here we report pharmacokinetic studies of the small
molecule p75NTR antagonist THX-B, and demonstrate that SCJ
delivery of THX-B attains retinal exposure at therapeutic levels
in the mouse model of diabetic retinopathy. Subconjunctival
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THX-B curbed expression of TNFa and a2M proinflammatory
agents decreased edema, and protected the ganglion cell layer
and nerve fiber layer with the same efficacy as THX-B IVT
injections.
Subconjunctival delivery of p75NTR inhibiting agents, which
afford long-lasting therapeutic benefits and no systemic
exposure, represent a promising novel approach for the
treatment of DR, and perhaps other chronic retinal pathologies
including glaucoma and AMD.
METHODS
Animals
All studies adhered to the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research, and were
approved by the McGill University Animal Care Committee.
We purchased C57Bl/6 wild-type mice (~25 g) and Sprague-
Dawley rats (~300 g) from Charles River Laboratories, Inc. (St.
Zotique, Quebec, Canada).
Ocular Drug Delivery
Mice were anesthetized with 3% isoflurane during IVT or SCJ
injections of a clear solution of THX-B p75NTR antagonist, or
vehicle. THX-B is a pharmacologic small molecule antagonist of
p75NTR19,20 and a competitive blocker of proNGF binding to
p75NTR.
For pharmacokinetic studies, we performed IVT injections
in the left eye, and SCJ injections in the right eye of the same
animal. In therapeutic studies of the diabetes mouse model, an
SCJ depot of THX-B p75NTR antagonist (right eye) or PBS
vehicle (left eye) were done in adult diabetic mice at 2.5 weeks
of ongoing disease.
Intravitreal Injections. Intravitreal injections were per-
formed as previously described.17 Briefly, a volume of 2.5 lL
containing a total of 5 lg THX-B was slowly delivered into the
mouse’s vitreous chamber using a Hamilton syringe, and
confirmed microscopically. After the injection, the syringe was
left in place for 30 seconds and slowly withdrawn to prevent
efflux.
Subconjuctival Injections. A volume of 20 lL containing
a total of 40 lg THX-B or 30 lL containing a total of 15 lg THX-
B, or corresponding volumes of vehicle (PBS) were injected.
The conjunctiva was gently pulled from the sclera using
tweezers. Half of the total volume of THX-B was delivered into
the superior subconjunctival space and the other half into the
nasal subconjunctival region using a microsyringe with a 33
gauge needle.
Sample Tissue Preparation and Organic Extraction
For retinal tissue preparation mice were humanely sacrificed at
different time points (5, 30, 60, 120, 180, and 360 minutes)
after the ocular injections. Then, the eyecups were enucleated,
rinsed in PBS, and transferred to a clean Petri dish. An incision
was made in the sclera at the posterior part of the eye, and
vitreous humor was aspirated with a micropipette. Afterward,
the cornea and lens were removed and the whole retina was
dissected. All samples were frozen in dry ice and stored at
808C or immediately processed. Retina tissue was homoge-
nized in 80 lL of methanol using a mini-homogenizer for 5
minutes at 48C. The homogenate was vortexed for 30 seconds
and left for 2 to 3 minutes on ice. Then, the samples were
centrifuged for 10 minutes at 8,000g. The supernatants were
collected and transferred into HPLC vials with insert to be
analyzed by HPLC.
Determination of THX-B Stability in Plasma
For plasma preparation, whole blood was collected from rats
by cardiac puncture under isoflurane anesthesia, and blood
was transferred into commercial heparinized tubes (Covidien,
Mansfield, MA, USA). Cells and platelets were removed and the
plasma supernatant was processed for organic extraction. We
incubated 2 lL of THX-B (2 mM) in 38 lL of plasma for 1, 30,
and 60 minutes at 48C or at 378C. For extraction of the
compound from plasma samples, 160 lL of methanol was
added to each tube and vortexed. Then, the samples were
centrifuged for 10 minutes at 8,000g. The supernatants were
collected and analyzed by HPLC.
Determination of THX-B Stability in Vitreous
Rats were euthanized and the eyes were enucleated. An
incision through the sclera was done at the posterior part of
the eyeball and the vitreous was quickly aspirated using a
pipette. To determine vitreous humor stability, 1 ll of THX-B (4
mM) was added to 19 ll of vitreous humor and incubated for
30, 60, 120, 180 and 240 min at 48C or 378C. The samples were
extracted in solvent as above, and analyzed by HPLC.
HPLC and Analysis
The concentration of THX-B was determined by HPLC. For each
sample, 20 lL of the supernatant collected after the organic
extraction was analyzed by HPLC (Waters Corp., Milford, MA,
USA) with a Harmony C18 analytical column (4.6 mm3 7.5 cm,
5.5 lm, 100A), injected with 20 lL/sample. Precolumn and
mobile phase A consisted of 10% acetonitrile (ACN), 90% water
(0.1% trifluoroacetic acid [TFA]); and B: 70% ACN, 30% water
(0.1% TFA) at a flow rate of 1 mL/minute. The gradient was
linear from 0 to 100% B for 10 minutes and UV detection at 275
nm. The retention time was 5.5 minutes. Quantification was
done by a linear regression analysis of peak area from a standard
curve. The calibration curve of THX-B showed excellent
linearity between peak areas and concentrations over the range
of 1 lM (0.74 lg/mL) to 100 lM (59.2 lg/mL) in water, with R2
value over 0.99. The limit of quantification of the present
method was 0.7 lM (0.52 lg/mL) corresponding to 10 ng in
samples. The recovery was close to 100%. Within-day and
interday coefficient of variation was lower than 3%.
Induction of Diabetes
Male 10-week-old mice received an intraperitoneal injection
(IP) of streptozotocin (STZ) (60 mg/kg; Sigma-Aldrich Corp., St.
Louis, MO, USA) dissolved in sodium citrate buffer (0.01 M, pH
4.5) on 5 consecutive days. After 1 and 6 weeks of injection
with STZ, blood glucose was measured using a glucometer
(Abbott Laboratories, Chicago, IL, USA), with fasting blood
glucose >17 mmol/l (300 mg/dL) considered as diabetic. Age-
matched, nondiabetic C57BL/6 mice injected with sodium
citrate buffer were used as controls.
Optic Coherence Tomography (OCT) Imaging
A noninvasive spectrometer-based Fourier-domain (FD)-OCT
system was used to acquire retinal images. Fourier domain OCT
is a noninvasive method that allows time-kinetic studies in the
same animal, with axial resolution in tissue nominally better
than 3 lm.21,22 In each B-scan, the thickness of the nerve fiber
layer–ganglion cell layer (GCL)–inner plexiform layer (IPL),
hereafter referred to as NGI, and the outer nuclear layer (ONL)
was measured at three adjacent points, with ImageJ software
(http://imagej.nih.gov/ij/; provided in the public domain by the
Less Invasive Delivery of p75 Antagonists in DR IOVS j June 2017 j Vol. 58 j No. 7 j 2853
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936282/ on 07/13/2017
National Institutes of Health, Bethesda, MD, USA) as described.17
Data are shown as average thickness in lm 6 SEM (absolute
values) in control versus diabetic mice 6 treatments.
Fluorescence ‘‘In Situ’’ Hybridization (FISH)
Retinal sections 20-lm thick were mounted onto gelatin-coated
glass slides, refixed in 4% paraformaldehyde, permeabilized
with proteinase K, and acetylated. Hybridization was carried
by incubating the slides with either 200 ng/mL of digoxigenin-
labeled TNFa or a2M antisense RNAs probes overnight at 728C
in a hybridization oven (Robbins Scientific, San Diego, CA,
USA), as previously described.17 As controls, hybridization
with either 200 ng/mL of digoxigenin-labeled TNFa or a2M
sense RNAs probes was performed on parallel slides using the
same experimental conditions. Images were obtained using a
confocal microscope (IX81; Olympus America, Inc., Center
Valley, PA, USA) equipped with commercial software (Fluoview
281 3.1; Olympus America, Inc.).
Immunohistochemistry
Whole eyes were enucleated and processed for immunohisto-
chemistry as previously described.17 Retinal cross-sections (20
lm) were sectioned using a cryostat (Leica Microsystems,
Wetzlar, Germany), and stained with antibodies specific for anti-
p75NTR (1:1000; a gift from P. Barker); anti-CRALBP (15051,
1:1000; Abcam, Cambridge, UK); anti-glial fibrillary acidic
protein (AB5804, 1:1000; Merck Millipore, Billerica, MA, USA);
anti-proNGF/NGF mAb (1:200019,23; prepared in-house); anti-
TNFa (AB2148P, 1:1000; Merck Millipore); or anti-alpha 2
macroglobulin (1:1000, Santa Cruz Biotechnology, Inc., Dallas,
TX, USA). Labeled secondary antibodies (goat anti-mouse IgG
AlexaFluor 488, and/or goat anti-rabbit IgG AlexaFluor 594;
Invitrogen Corp., Carlsbad, CA, USA) were used for colocaliza-
tion studies. Images were obtained using a confocal microscope
(Olympus America, Inc.) equipped with commercial software
(Olympus America, Inc.). As immunostaining controls, adjacent
sections were processed by substituting primary with irrelevant
primary or by omitting the primary, followed by the proper
secondary. In all cases, background levels were undetectable.
Western Blotting
Dissected whole retinas were solubilized and samples (30 lg)
were resolved on SDS-PAGE gels (8%–12%), and transferred by
Western blotting. Membranes were incubated overnight at 48C
with mouse anti-b-actin (sc-47778, 1:1000; Santa Cruz Biotech-
nology); rabbit antibody to p75NTR (1:1000; a gift from P. Barker);
rabbit anti-TNFa (AB2148P, 1:2000; Merck Millipore), rabbit anti-
alpha 2 macroglobulin (1:2000; Santa Cruz Biotechnology); or rat
anti-pro-NGF/NGF (1:200). After washing, membranes were
incubated with 1:5000 horseradish peroxidase-conjugated anti-
mouse or anti-goat or anti-rabbit secondary antibodies (Merck
Millipore) for 2 hours at room temperature. Membranes were
imaged with a commercial imager (LAS-3000; Fujifilm, Tokyo,
Japan) and bands were assessed using densitometry plugins in
ImageJ 1.47 software. The molecular weight (Mr) of bands were
calculated using standard markers.
Reverse-Transcription PCR and Quantitative Real-
Time PCR
Retina samples were processed as previously described.17 Total
RNA (1 lg) was reverse-transcribed to cDNA and analyzed by
quantitative real-time PCR on a real-time PCR system (ABI 7500;
Applied Biosystems, Foster City, CA, USA) and using a master
mix (iQTM SYBRt Green Supermix; Bio-Rad Laboratories,
Hercules, CA, USA) with primers targeting, TNFa and GAPDH.
Mouse TNFa forward 50 GAGTCCCAGGTCTACTTT 30 reverse 50
CAGGTCACTGTCCCAGCATCT 30 primers were used to gener-
ate specific fragments. All primers were used at 100 nM. The
reaction was performed in triplicate with a quantitative (q)PCR
system (Mx3000P; Agilent Technologies, Santa Clara, CA, USA).
Amplification reaction data were analyzed using the comple-
mentary analysis software (Agilent Technologies). Target gene
expression was normalized to the average expression of the
housekeeping gene GAPDH forward 50 CACCACCTTGATG
TCATC 30 reverse 50AGCCCAGAACATCCCTG 30. Quantitative
analysis of gene expression was assessed using the DDCT
quantification.
Vascular Permeability Assay
Evans blue permeation was analyzed by measuring albumin-
Evans blue complex leakage from retinal vessels as previously
described.17 Briefly, animals were injected intravenously with a
solution of Evans blue (2% wt/vol dissolved in PBS). After 48
hours, animals were killed, the whole eyes enucleated,
immediately embedded in OCT compound, and cross-sections
were prepared. Images by immunofluorescence microscopy
were obtained using identical exposure time, brightness, and
contrast settings. For each experimental condition, at least six
images were acquired from three sections cut from different
areas of the retina (n ¼ 3 retinas per group). The area of the
Evans blue permeation was measured using ImageJ software;
an arbitrary rectangle that included all layers of the retina—
FIGURE 1. Stability and pharmacokinetics THX-B. (A) Plasma and
vitreous stability of THX-B was quantified by HPCL. The concentration
of THX-B in plasma were measured after spiking the plasma with THX-
B (2 mM) and incubating at 48C or 378C for the indicated times,
followed by precipitation with 4x MeOH volume. (B) Concentration of
THX-B detected in healthy mice retinas, at the indicated times after
delivery of 5 lg THX-B (IVT) or 40 lg THX-B (SCJ). The maximal
concentration of THX-B was observed at 30 minutes after injection and
decreased at 60 minutes. At both time points, the concentration of
THX-B in the retina observed was very similar regardless of the method
of delivery used.
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GCL; IPL; inner nuclear layer [INL]; ONL; photoreceptor layer
[PhR]; and RPE—was drawn and the area in pixels quantified.
Data are shown as the average area (in pixels) 6 SEM in
control versus diabetic injected once with vehicle or THX-B.
Statistical Analysis
Results are presented as mean 6 SEM for all studies. We used 2-
way ANOVA (for OCT) and 1-way ANOVA (for all other
experiments), with significance of a ¼ 0.05 or higher for
processing data. Bonferroni post hoc analysis was used for
calculating significance between groups. Changes in NGI
thickness for treated and untreated retinas were analyzed by
2-tailed Student’s t-tests for significance between two means.
RESULTS
Stability of THX-B in Plasma
We measured the THX-B plasma levels at 48C and 368C by
spiking plasma with THX-B (2 mM), followed by precipitation
with 4x MeOH after 1, 30, and 60 minutes of incubation. The
results showed very small fluctuations of the THX-B concen-
tration in plasma at the time points tested, regardless of the
temperature (Fig. 1A). The recovery of THX-B was close to
100%. These data indicate that the THX-B compound is stable
in plasma, and that it does not bind to proteins. Similar data
was obtained when testing for THX-B stability in vitreous, for
up to 4 hours (Fig. 1A).
Detection of THX-B in Retina After IVT and SCJ
Injections
Next, we studied the pharmacokinetics of THX-B in the retina
at 30 and 60 minutes after IVT or SCJ injections. The right eyes
were injected with 5 lg of THX-B intravitreally, and the left
eyes of the same animals were injected with 40 lg of THX-B by
the subconjunctival route.
For both, IVT or SCJ injections, the maximum concentration
of THX-B in retina tissue was detected 30 minutes after
delivery of the compound. At 30 minutes, THX-B concentra-
tions of 1.5 6 0.645 ng/mg of retinal protein following IVT
injections, and 1.7 6 0.179 ng/mg of retinal protein following
FIGURE 2. Subconjuctival delivery of THX-B in diabetes exerts the same protective effect as intravitreal administration. (A) Time-dependent changes
in NGI thickness 6 SD (n ¼ 4 eyes). Thickness of NGI is lost progressively in the diabetic retina treated with vehicle. Subconjuctival THX-B
treatment significantly preserved the NGI structure at weeks 5 and 6 (P < 0.05). (B) Representative sections of B-scans OCT images in 6-week-
diabetic mice 6 subconjunctival THX-B or vehicle (PBS; injections at week 2.5 of diabetes); compared to age-matched control healthy animals.
Vertical white lines delimit the thickness of the NGI, INL, and ONL layers. Scale bar: 100 lm. (C) Upper panel: quantification of NGI layer thickness
from B-scans OCT images at weeks 5 and 6 after onset of diabetes. Subconjuctival THX-B treatment was significantly protective (**P < 0.01 at week 5
and ***P < 0.001 at week 6; n¼3 independent experiments, total of 9 mice per group) in the NGI. Lower panel: percentage of NGI loss in diabetes
comparing THX-B relative to vehicle-treated retinas (set at maximal NGI loss). Treatment with THX-B significantly reduced NGI damage at weeks 5
and 6 (***P < 0.001, n¼ three independent experiments, total of nine mice per group). All statistical analyses are 2-way ANOVA with significance a
< 0.05, followed by Bonferroni’s correction for multi-comparisons.
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SCJ injections were detected. At 60 minutes, the amount of
THX-B decayed to 0.9 6 0.267 ng/mg after IVT injections and
to 0.4 6 0.027 ng/mg after SCJ delivery of THX-B (Fig. 1B). At
120 minutes, the concentration of THX-B in the retina was
under the limit of detection for both routes of administration
(data not shown), suggesting clearance due to vitreous
exchange and/or draining into systemic circulation. These data
were replicated in two independent experiments (n ¼ 2 or 3
mice per group per experiment).
These data indicate that administration of THX-B by the SCJ
route delivers to the retina the similar amount of THX-B as the
IVT route. In intravitreal delivery, there is a clearance
mechanism likely through exchange or renewal of vitreous
fluid that reduces the THX-B concentration available to
permeate from the vitreous to the retina. In subconjunctival
delivery, clearance may be associated with choroid vasculature
or the continuous migration of the compound through the
sclera.
Subconjuctival Administration of THX-B in
Diabetes Preserves Retinal Structure
We previously demonstrated early p75NTR upregulation in the
retina, ~1 week after the onset in diabetes; and that
antagonizing p75NTR with intravitreal THX-B preserved retinal
structure and prevented diabetes-induced neuronal loss.17 We
investigated whether SCJ injection of THX-B achieved the same
protection. At 2.5 weeks after onset of diabetes THX-B was
injected into the conjunctiva of one eye and the contralateral
eye was injected with control PBS vehicle. The structural
changes of the retina were quantified in longitudinal studies by
OCT, a noninvasive technique validated to correlate with
retinal ganglion cell (RGC) numbers and nerve fiber layer
health. In each group, comprised of 4 animals, we compared
the right and left eyes of each animal. We performed OCT
longitudinally for up to 6 weeks of diabetes, measuring RGC
cell bodies and fibers in the NGI (Fig. 2A).
In diabetic retinas (injected SCJ with PBS vehicle control)
the NGI thickness decreased progressively and was significant-
ly lower after 5 weeks of diabetes compared to age-matched
nondiabetic eyes (P < 0.05). Treatment of diabetic eyes with
either 2 lg THX-B IVT or with two different doses of THX-B SCJ
(15 or 40 lg) protected the NGI from thinning even at week 6
of diabetes (P < 0.05 to control diabetic retina). There were no
differences in preservation of retinal structures achieved by
SCJ and IVT deliveries (Fig. 2A). Protection by subconjunctival
THX-B was achieved by the lower dose 15 lg THX-B SCJ, and
this dose was used for further experiments.
A more detailed longitudinal study by OCT confirmed the
protective effect of NGI by THX-B (15 lg, SCJ) with significant
protection even at 6 weeks after the onset of diabetes (44.49 6
0.69 lm versus 38.16 6 2.7 lm; P < 0.001; Figs. 2B, 2C).
Setting the NGI damage in vehicle-treated diabetic eyes as
maximal (100%), the protection conveyed by THX-B to the NGI
of diabetic eyes was ~50% at week 5 (P < 0.001) and 70% at
week 6 (P < 0.001; Fig. 2C).
Diabetic retinopathy causes damage specifically to the NGI
layers, and within the time frame of the experiments there
were no structural alterations to the INL (where the Mu¨ller and
bipolar cell bodies reside) or to the ONL (containing cone and
rods photoreceptor cell bodies). These unaffected layers are
useful as internal control of specific damage and specific
rescue by delivery of p75NTR antagonists.
Together these data indicate that in ongoing diabetic
retinopathy a single subconjunctival THX-B has a significant
long-lasting protective effect of the NGI, comparable to a single
injection of intravitreal THX-B.
Subconjuctival Injection of THX-B Reduces the
Production of Neurotoxic Factors
A previous study in our laboratory showed that in diabetic
retinopathy there is an increase of cytotoxic factors a2M and
TNFa, associated with the upregulation of p75NTR and pro-NGF.
Production of these neurotoxic factors are inhibited by
FIGURE 3. Subconjunctival THX-B reduces neurotoxic factors a2M and TNFa proteins. (A) Expression of a2M, p75NTR, proNGF, and TNFa in whole
retinas analyzed by Western blots of retinal samples from week-6 diabetic mice 6 treated at week 2.5 of diabetes, compared to age-matched control
healthy mice. (B–E) Histograms show quantification of Western blots. *P < 0.05, **P < 0.01, ***P < 0.001 relative to control healthy animals (n¼ 3
independent experiments). Treatments were at week 2.5 of diabetes and sample collection and analyses were done at week 6. THX-B prevented the
increase of a2M, proNGF, and TNFa without affecting p75NTR levels.
Less Invasive Delivery of p75 Antagonists in DR IOVS j June 2017 j Vol. 58 j No. 7 j 2856
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936282/ on 07/13/2017
intravitreal THX-B.17 Here, we aimed to study the effect of
subconjunctival THX-B using the same experimental paradigm,
at week 6 after the induction of diabetes.
Compared to healthy controls, diabetic retinas increased
a2M protein ~2-fold (a2M, 1.74 6 0.0147; P < 0.001, n¼ 3),
increased pro-NGF protein ~3-fold (pro-NGF, 2.75 6 0.424; P
< 0.05, n ¼ 3) and increased TNFa protein ~3.5-fold (TNFa,
3.65 6 0.454; P < 0.01, n ¼ 3; Fig. 3A, quantified in Figs. 3B,
3D, 3E).
The increases in a2M, TNFa, and pro-NGF were significantly
normalized by treatment with subconjunctival THX-B, com-
pared to vehicle-contralateral diabetic eyes (n¼3; a2M, 1.23 6
0.057, P < 0.001; pro-NGF, 1.10 6 0.259, P < 0.05; and TNFa,
1.82 6 0.461, P < 0.05; Fig. 3A, quantified in Figs. 3B, 3D, 3E).
It is noteworthy that THX-B subconjunctival injection did not
significantly decrease p75NTR protein levels (Fig. 3A, quantified
in Fig. 3C).
Immunohistochemical studies in retinal sections demon-
strated that in diabetic retinas, the a2M protein was mainly
FIGURE 4. Proteins a2M and TNFa are specifically increased in retinal layers affected in diabetes, and subconjunctival THX-B reduces these
neurotoxic factors. Confocal microscopy images showing the induction and distribution of (A) a2M or (B) TNFa proteins in retina at week 6 of
diabetes 6 treatment; compared to age-matched control healthy animals. Treatments were at week 2.5 of diabetes. Protein a2M (green) was
preferentially expressed in the INL and the end-feet of Mu¨ller cells (red), as revealed by coexpression with CRALBP. Tumor necrosis factor alpha
(green) was almost exclusively expressed in cells located in the GCL, surrounded by the end-feet of Mu¨ller cells (red). Nuclei are counterstained
with DAPI. Images are representative of three independent experiments. Scale bar: 25 lm. (C, D) Quantification of the expression of a2M and TNFa
protein in total retina relative to control healthy. GCL, INL, OPL, and PhR layers were quantified. THX-B significantly decreased a2M and TNFa
compared to contralateral diabetic–vehicle (Veh)-treated retinas. ***P < 0.001; n ¼ 3 independent experiments each with two animals/group.
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located in the end-feet of Mu¨ller cells identified by cellular
retinaldehyde-binding protein (CRALBP) and in the INL (Fig.
4A), whereas TNFa protein was almost exclusively in the GCL
(Fig. 4B). Parallel immunohistochemical studies using sections
of contralateral diabetic retinas treated with subconjunctival
THX-B show almost completely decreased a2M and TNFa
expression to the basal levels detected in control healthy
retinas (Figs. 4A–D).
Since a2M and TNFa are soluble factors, we further verified
their mRNA cellular expression pattern. Retinal sections of
diabetic mice 6 weeks after STZ injection were studied by in situ
mRNA hybridization. Our data show significant increases in a2M
mRNA (P < 0.01) and TNFa mRNA (P <0.01) in the GCL and
INL of diabetic retinas compared to control healthy retinas. As
technical control for the specificity of in situ hybridization, using
sense probes for TNFa or a2M showed undetectable levels (data
not shown). Hence, most of the de novo upregulation of both
cytokines was observed in the GCL and INL, the main retinal
layers affected in the disease. In contralateral diabetic eyes a2M
and TNFa mRNA levels were significantly reduced by subcon-
junctival THX-B treatment (P < 0.001 and P < 0.01,
respectively; Figs. 5A, 5B, quantified in Figs. 5C, 5D).
In situ hybridization results were corroborated by qPCR
quantification of TNFa-mRNA at 6 weeks after the induction of
diabetes. We found TNFa-mRNA was significantly increased in
retinas of diabetic mice compared to control healthy retinas
FIGURE 5. Subconjunctival THX-B reduces the mRNA levels of neurotoxic factors a2M and TNFa. Fluorescence in situ hybridization shows
induction and distribution of (A) DIG-labeled a2M or (B) TNFa antisense RNAs probes (red) in mice retina after 6 weeks of diabetes 6 treatment;
compared to age-matched control healthy animals. Treatments were at week 2.5 of diabetes. Nuclei are counterstained with DAPI. Images are
representative of three independent experiments. Scale bar: 25 lm. (C, D) Quantification of the expression of a2M and TNFa mRNAs in total retina,
relative to control healthy retinas. Layers of GCL, INL, OPL, and PhR were quantified. THX-B significantly decreased a2M and TNFa mRNAs
compared to contralateral diabetic–vehicle-treated retinas. *P < 0.05, **P < 0.01; n¼ 3 independent experiments each with two animals/group. (E)
Quantification of the levels of TNFa transcript by qPCR on whole retinas after 6 weeks of diabetes 6 treatment; compared to age-matched control
healthy animals. Treatments were at week 2.5 of diabetes. *P < 0.05, **P < 0.01; n¼ 3.
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(2.3 6 0.196; P < 0.01, n ¼ 3; Fig. 5E); and the increase was
significantly diminished by treatment with subconjunctival
THX-B (1.4 6 0.358; P < 0.05, n ¼ 3; Fig. 5E).
Together, these data suggest that pharmacologic inhibition
of p75NTR, including a relatively benign SCJ delivery, attenuates
the production of pro-inflammatory cytokines in the retina and
affords structural preservation of retina with the same efficacy
as previously reported IVT treatments.
Subconjuctival Administration of THX-B Reduces
Vascular Permeability in Diabetes
The pathophysiology of diabetes is characterized by a cascade
of events that include loss of blood–retinal barrier function
causing extravasation and retinal edema. Here, we analyzed the
effect of subconjunctival THX-B on extravasation in vivo, using
the Evans blue vascular permeability assay, in mice at 8 weeks
post-STZ. Our results demonstrate that subconjunctival THX-B
treatment caused a significant decrease in vascular leakage
compared to age-matched diabetic nontreated mice (2.31 6
0.17 vs. 4.45 6 0.25 normalized area values relative to control
healthy, P < 0.01; Fig. 6A, quantified in Fig. 6B).
These data suggest that subconjunctival THX-B reduces
extravasation, which is beneficial to prevent key aspects of the
diabetic pathology in the retina. In addition, it is likely that
ameliorating vascular permeability prevents extravasation of
a2M and other inflammatory factors present in serum, hence
further improving the environment of the diseased retina.
Subconjuctival Administration of THX-B in
Diabetes Affords a Long-Lasting Preservation of
Retinal Structure
Given that a single injection of THX-B (SCJ at week 2.5 of
diabetes) had detectable physiologic benefits at week 8 of
diabetes, we investigated benefits at longer time-points.
A quantitative longitudinal study by OCT examined the
effect of THX-B (SCJ at week 2.5 of diabetes) on the NGI up to
FIGURE 6. Subconjuctival administration of THX-B reduces pathologic vascular permeability in diabetes. (A) Confocal images of retinal sections
from 8-week-diabetic mice 6 treatment; compared to age-matched control healthy animals. Treatments were at week 2.5 of diabetes. Red signal
depicts leakage of Evan blue into the retina. Nuclei are counterstained with DAPI. Scale bar: 25 lm. (B) Quantification of Evan blue images. Data are
shown as the average area (in pixels) 6 SEM and as normalized area relative to control healthy mice. Treatment with subconjunctival THX-B
significantly reduces Evans blue extravasation compared to age-matched diabetic untreated mice. *P < 0.05, ***P < 0.001, n ¼ 3.
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week 10 of diabetes. In control diabetic retinas, thinning of the
NGI progressed from weeks 8 to 10, compared to age-matched
nondiabetic retinas (P < 0.05). Treatment of diabetic mice
with THX-B SCJ (15 lg) prevented thinning of the NGI until
week 10 of diabetes (P < 0.05 to control diabetic retina; Figs.
7A, 7B). It was not possible to test the mice past week 10 due
to systemic consequences of diabetes.
Setting the NGI damage in vehicle-treated diabetic eyes as
maximal (100%), the reduction in NGI damage achieved by
THX-B at each week was ~50% for weeks 8 and 9 (P < 0.001)
and ~35 % for week 10 (P < 0.001; Fig. 7C).
As internal control, indicating that diabetes specifically
affects RGCs and their fibers, there were no structural
alterations to the INL or to the ONL even at 10 weeks of
diabetes (data not shown).
These data indicate that the NGI structure (containing RGCs
and their fibers) degenerates chronically during diabetes. The
p75NTR inhibitor THX-B specifically protects the NGI, and in
ongoing diabetic retinopathy a single dose of subconjunctival
THX-B has a significant long-lasting protective effect of that
retinal structure.
DISCUSSION
We report on a novel disease-modifying target p75NTR, and
studies leading to the therapeutic use of small molecule
antagonist THX-B delivered as a relatively benign SCJ depot, for
treatment of serious, chronic, and still incurable diseases such
as DR but also potentially AMD and glaucoma.8,10–12
The unique anatomy of the eye and the blood–retinal
barrier protects the retina from the internal and the external
environments, while maintaining the needed optical transpar-
ency and light detection by retinal neurons. This poses
challenges to drug delivery to the retina. Systemic drug
delivery often does not afford permeation to retina achieving
therapeutic concentrations, or this route may require high
drug doses, or cause undesirable effects elsewhere in the body.
Topical administration is useful, but very few agents achieve
therapeutic concentrations in the vitreous humor or the retina.
Hence, intravitreal injection has become a commonly used
route for administration of compounds targeting the retina.
Although this route is effective, it is invasive and repeated
interventions carry a high burden.3,9,24
In addition to the retinal drug delivery challenge, there are
very few new targets and mechanisms validated. This is
especially significant given that there are very few targets that
play an etiologic role in the neuroglia-vascular DR pathology
comprising inflammatory, edema, and neuronal death.17 Here,
we demonstrate that acute subconjunctival administration of
THX-B achieved concentrations in the retina sufficient to
reduce edema, to decrease the production of retinal inflam-
matory cytokines TNFa and a2M, and to preserve the neuronal
retinal structure for prolonged periods of time. The benefit is
comparable to or better than IVT injection of THX-B.
FIGURE 7. Subconjuctival administration of THX-B affords a long-lasting protective effect on the retinal structure during diabetes. (A)
Representative sections of B-scan OCT images from diabetic mice treated with either vehicle (PBS) or subconjunctival THX-B (treatments at week
2.5 of diabetes). Quantifications were done after 8, 9, and 10 weeks following the onset of diabetes, and compared to age-matched control healthy
animals. Scale bar: 100 lm. Vertical white lines delimit the thickness of the NGI, INL, and ONL layers. (B) Time-dependent changes in NGI
thickness 6 SEM (n ¼ 4 eyes). Thickness of NGI is lost progressively in the diabetic retina treated with vehicle. Subconjuctival THX-B treatment
significantly preserved the NGI structure from weeks 8 to 10 (***P < 0.001, **P < 0.01). (C) Percent NGI loss comparing THX-B relative to vehicle.
Treatment with THX-B significantly reduced NGI damage at all time points studied (***P < 0.001, n ¼ 4 mice per group). Two-way ANOVA with
significance at a < 0.05, followed by Bonferroni’s correction for multi-comparisons.
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We could not find relevant documentation regarding the
concentrations of small molecule drugs to treat posterior-
segment pathologies, using the SCJ route. However, detection
of agents in the vitreous humor after SCJ delivery has been
reported as early as 15 to 30 minutes.3 Data documenting fast
kinetics and accumulation of agents in the aqueous and
vitreous following SCJ injection could explain the rapid entry
of THX-B into the retina. For example, an SCJ injection of
mannitol achieves maximum concentration in the aqueous
and in the vitreous between 30 and 60 minutes, and
disappears from the vitreous after 3 hours.9 In humans, the
maximum dexamethasone concentration in aqueous humor
was detected at 2.5 hours after SCJ injection and in the
vitreous at 3 hours.7 A study using AlexaFluor 647–labeled
pRNA nanoparticles reached the retina 6 hours after SCJ
delivery.25 The large and accessible surface area of the sclera
and high degree of hydration and relatively absence of
cells5,26 may facilitate the diffusion of small water-soluble
molecules such as THX-B.
The chemical properties of THX-B would account for its
fast diffusion from the vitreous to the retina. Based on these
data, we hypothesize that this may be the route for
subconjunctival THX-B. Even if a much faster delivery of the
drug to the retinal tissue in case of IVT administration is
expected to occur, both routes have comparable efficiency to
target the retina.
Regarding drug elimination, compounds delivered by IVT
and SCJ injections can be cleared quickly. Upon IVT
administration, agents can be cleared by diffusion or filtration
to the aqueous humor, or by permeation across the BRB due to
passive or active transport.5 Upon SCJ administration, agents
can be cleared from the depot by diffusion into surrounding
tissues and also by rapid elimination via lymphatic and blood
vessels of the conjunctiva.5,6,26,27
We would postulate that THX-B rapidly reaches the retina
most likely by direct transcleral diffusion.7 The sclera has a
large and accessible area and it is highly hydrated, which
renders it conducive to water-soluble or amphipathic agent
such as THX-B. Moreover, the sclera has few proteolytic
enzymes or protein-binding sites that can degrade or
sequester compounds.3 The absorption of the SCJ drug into
the systemic circulation and then recirculation back to the
retina is highly unlikely given the relatively low doses
administered, the large volume of distribution that would
result in this case, and the fact that after SCJ delivery we did
not detect THX-B in circulation to a quantitative limit of
detection of 5 ng.
Remarkably, acute delivery of THX-B at 2.5 weeks after the
onset of diabetes affords a long-term therapeutic effect for
multiple pathologic endpoints of DR, lasting up to 10 weeks,
even though the THX-B is cleared from the SCJ depot and the
retina. Most likely, inhibition of the multifactorial activities of
p75NTR resets the retinal environment to homeostasis.
A therapeutic effect of p75NTR inhibition has been reported
after IVT delivery in DR17 and in experimental glaucoma,18
optic nerve axotomy.19 Hence, it will be important to test the
newly reported SCJ delivery route for p75NTR antagonists in
glaucoma, retinitis pigmentosa, AMD, and other chronic retinal
diseases that require long-lasting therapeutic efficacy with
reduced frequency of intervention.
In sum, our experimental observations demonstrate the
efficacy of subconjunctival THX-B delivery, and support the
view that p75NTR antagonists may be novel therapeutics with a
wide spectrum of action. Subconjunctival delivery of p75NTR
inhibiting agents that yield long-lasting therapeutic benefits
represent a less-invasive approach to modify disease through a
promising novel target.
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